Certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.] MASTER TRADEMARK ASSIGNMENT AGREEMENT
Exhibit 10.7
[Certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.]
MASTER TRADEMARK ASSIGNMENT AGREEMENT
This Master Trademark Assignment Agreement (this “Assignment”) is made and entered into effective as of May 5, 2022 (the “Execution Date”) and effective as of the Completion (as defined below) (the “Effective Date”) by and among Intercept Pharmaceuticals, Inc., a company incorporated in Delaware, and RXF Technologies, Inc., a company incorporated in Delaware (collectively, the “Sellers”), and Mercury Pharma Group Limited, a company incorporated in England (the “Purchaser”). The Sellers and the Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS, the Sellers are the sole and exclusive owners in the applicable jurisdiction of the Trademarks set forth on Schedule A attached hereto and made part hereof (collectively, the “Purchased Trademarks”); and
WHEREAS, in connection with (a) that certain Share Purchase Agreement, dated as of May 5, 2022 (the “Share Purchase Agreement”), by and among Intercept Pharmaceuticals, Inc., Intercept Pharmaceuticals LLC and the Purchaser, (b) that certain Sublicense Agreement, dated as of May 5, 2022 (the “Sublicense Agreement”), by and among Intercept Pharma Europe Ltd and the Purchaser, and (c) Intercept Pharma Europe Ltd. and Advanz Pharma Services (UK) Limited are entering into that certain Business Transfer Agreement as of the Execution Date whereby, upon the Completion Date, Licensee shall acquire the business of certain non-US subsidiaries of Intercept, the Purchaser wishes to acquire from the Sellers, and the Sellers wish to assign, transfer, convey and deliver to the Purchaser, the Purchased Trademarks.
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth and set forth in the Share Purchase Agreement and the other Ancillary Agreements, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
IN WITNESS WHEREOF, the undersigned have duly executed this Assignment as of the Execution Date.
| | | ||
| | | | |
| | | | |
| | | By: | /s/ Xxxxxx Xxxx |
| | | Name: | Xxxxxx Xxxx |
| | | Title: | Authorised Signatory |
| | | | |
| | | | |
| | | Mercury Pharma Group Limited | |
| | | | |
| | | By: | /s/ Xxxxxxx Xxxxxxxx |
| | | Name: | Xxxxxxx Xxxxxxxx |
| | | Title: | Director |
| | | | |
| | | | |
| | | RXF Technologies, Inc. | |
| | | | |
| | | By: | /s/ Xxxxx Xxxxxxx |
| | | Name: | Xxxxx Xxxxxxx |
| | | Title: | President |
Schedule A
Purchased Trademarks
[***]